{"id":"angiotensin","rwe":[{"pmid":"41912901","year":"2026","title":"[Extrapulmonary sarcoidosis with multiorgan involvement: a complex case with renal, neurological, and gastrointestinal manifestations].","finding":"","journal":"Innere Medizin (Heidelberg, Germany)","studyType":"Clinical Study"},{"pmid":"41912806","year":"2026","title":"The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.","finding":"","journal":"Nature medicine","studyType":"Clinical Study"},{"pmid":"41910487","year":"2026","title":"Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury: Insights from the Chronic Renal Insufficiency Cohort Study.","finding":"","journal":"Kidney360","studyType":"Clinical Study"},{"pmid":"41909498","year":"2026","title":"Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis.","finding":"","journal":"Kidney diseases (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41909425","year":"2026","title":"A Minimalist Approach With Maximum Outcomes: Intralesional Steroid Therapy in Orofacial Sarcoidosis.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"_fda":{"id":"db7a3372-cd0e-412e-a8e2-90b5fdcf3e3e","set_id":"727d1102-fc46-46f8-b78e-fd13f0738fe4","openfda":{"nui":["N0000192562","N0000009908"],"unii":["M089EFU921"],"route":["INTRAVENOUS"],"rxcui":["1999007"],"spl_id":["db7a3372-cd0e-412e-a8e2-90b5fdcf3e3e"],"brand_name":["ANGIOTENSIN II"],"spl_set_id":["727d1102-fc46-46f8-b78e-fd13f0738fe4"],"package_ndc":["68083-553-01"],"product_ndc":["68083-553"],"generic_name":["ANGIOTENSIN II"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Vasoconstriction [PE]"],"substance_name":["ANGIOTENSIN II"],"pharm_class_epc":["Vasoconstrictor [EPC]"],"manufacturer_name":["Gland Pharma Limited"],"application_number":["ANDA216966"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk Summary The published data on angiotensin II use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have not been conducted with Angiotensin II. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or other distributive shock is likely to increase the risk of maternal and fetal morbidity and mortality."],"overdosage":["10 OVERDOSAGE Overdose of Angiotensin II would be expected to result in hypertension, necessitating close monitoring and supportive care. Effects are expected to be brief because the half-life of angiotensin II is less than one minute."],"description":["11 DESCRIPTION Angiotensin II is a naturally occurring peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure. Angiotensin II Injection is a sterile, aqueous solution of synthetic human angiotensin II for intravenous administration by infusion. Each 1 mL of Angiotensin II Injection contains 2.5 mg angiotensin II equivalent to an average of 2.9 mg angiotensin II acetate, 25 mg mannitol, and Water for Injection adjusted with sodium hydroxide and/or hydrochloric acid to pH of 5.5. The chemical name of the synthetic angiotensin II acetate is L-Aspartyl-L-arginyl-L-valyl-L­-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine, acetate salt. The counter ion acetate is present in a non-stoichiometric ratio. It is a white to off-white powder, soluble in water. The structure of angiotensin II acetate is shown below. Molecular formula: C50H71N13O12 • (C2H4O2) n; (n= number of acetate molecules; theoretical n= 3) Average molecular weight: 1046.2 (as free base). angiotensin-II-chemcial-structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1. How Supplied Angiotensin II Injection is a clear, aqueous solution for administration by intravenous infusion supplied as a single dose vial as follows: • 2.5 mg/mL vial: NDC 68083-553-01: A carton of one 1 mL single dose vial containing 2.5 mg angiotensin II (as a sterile liquid). 16.2. Storage and Handling • Angiotensin II Injection vials should be stored in the refrigerator (36-46°F, 2-8°C). • Discard prepared diluted solution after 24 hours at room temperature or under refrigeration. Manufactured by: Gland Pharma Limited Hyderabad -502307, INDIA Revised: September, 2022","16.1. How Supplied Angiotensin II Injection is a clear, aqueous solution for administration by intravenous infusion supplied as a single dose vial as follows: • 2.5 mg/mL vial: NDC 68083-553-01: A carton of one 1 mL single dose vial containing 2.5 mg angiotensin II (as a sterile liquid)."],"geriatric_use":["8.5 Geriatric Use In ATHOS-3, 48% of the total patient population was aged 65 years and older. There was no significant difference in safety or efficacy between patients less than 65 and those 65 years or older when treated with Angiotensin II."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of Angiotensin II in pediatric patients have not been established."],"effective_time":"20250604","clinical_studies":["14 CLINICAL STUDIES 14.1. ATHOS-3 The Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) trial was a double-blind study in which 321 adults with septic or other distributive shock who remained hypotensive despite fluid and vasopressor therapy were randomized 1:1 to Angiotensin II or placebo. Doses of Angiotensin II or placebo were titrated to a target mean arterial pressure (MAP) of ≥ 75 mmHg during the first 3 hours of treatment while doses of other vasopressors were maintained. From Hour 3 to Hour 48, Angiotensin II or placebo were titrated to maintain MAP between 65 and 70 mmHg while reducing doses of other vasopressors. The primary endpoint was the percentage of subjects who achieved either a MAP ≥ 75 mmHg or a ≥ 10 mmHg increase in MAP without an increase in baseline vasopressor therapy at 3 hours. 91% of subjects had septic shock; the remaining subjects had other forms of distributive shock such as neurogenic shock. At the time of study drug administration, 97% of subjects were receiving norepinephrine, 67% vasopressin, 15% phenylephrine, 13% epinephrine, and 2% dopamine. 83% of subjects had received two or more vasopressors and 47% three or more vasopressors prior to study drug administration. 61% of subjects were male, 80% were White, 10% were Black, and 10% were other races. The median age of subjects was 64 years (range: 22-89 years). Patients requiring high doses of steroids, patients with a history of asthma or bronchospasm, and patients with Raynaud’s syndrome were not included. The primary endpoint was achieved by 70% of patients randomized to Angiotensin II compared to 23% of placebo subjects; p < 0.0001 (a treatment effect of 47%). Figure 1 shows the results in all patients and in selected subgroups. Figure 1: ATHOS-3: Primary Endpoint – Overall Result and Results in Selected Subgroups NE Equiv = norepinephrine equivalent dose: the sum of all vasopressors doses with each vasopressor dose converted to the clinically equivalent norepinephrine dose Note: The figure above presents effects in various subgroups, all of which are baseline characteristics. The 95% confidence limits that are shown do not take into account the number of comparisons made, and may not reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted. In the Angiotensin II -treated group, the median time to reach the target MAP endpoint was 5 minutes. The effect on MAP was sustained for at least the first three hours of treatment. The median dose of Angiotensin II was 10 ng/kg/min at 30 minutes. Of the 114 responders at Hour 3, only 2 (1.8%) received more than 80 ng/kg/min. Patients were not necessarily on maximum doses of other vasopressors at the time of randomization. The effect of Angiotensin II when added to maximum doses of other vasopressors is unknown. Mortality through Day 28 was 46% on Angiotensin II and 54% on placebo (hazard ratio 0.78; 95% confidence interval 0.57 – 1.07). angiotensin-fig-1"],"pharmacodynamics":["12.2 Pharmacodynamics For the 114 (70%) patients in the Angiotensin II arm who reached the target MAP at Hour 3, the median time to reach the target MAP endpoint was approximately 5 minutes. Angiotensin II is titrated to effect for each individual patient."],"pharmacokinetics":["12.3 Pharmacokinetics Following intravenous infusion of angiotensin II in adults with septic or other distributive shock, serum levels of angiotensin II are similar at Baseline and Hour 3 after intravenous infusion. After 3 hours of treatment, however, the serum level of angiotensin I (the angiotensin II precursor peptide) is reduced by approximately 40%. Distribution: No specific studies were conducted that examined the distribution of Angiotensin II. Metabolism and Excretion: No specific studies were conducted that examined the metabolism and excretion of Angiotensin II. The plasma half-life of IV administered angiotensin II is less than one minute. It is metabolized by aminopeptidase A and angiotensin converting enzyme 2 to angiotensin-(2-8) [angiotensin III] and angiotensin-(1-7), respectively in plasma, erythrocytes and many of the major organs (i.e., intestine, kidney, liver and lung). Angiotensin II type 1 receptor (AT1) mediated activity of angiotensin III is approximately 40% of angiotensin II; however, aldosterone synthesis activity is similar to angiotensin II. Angiotensin-(1-7) exerts the opposite effects of angiotensin II on AT1 receptors and causes vasodilation. Specific Populations No formal pharmacokinetic studies were conducted with Angiotensin II in the following specific populations. Renal Impairment The clearance of angiotensin II is not dependent on renal function. Therefore, the pharmacokinetics of Angiotensin II are not expected to be influenced by renal impairment. Hepatic Impairment The clearance of angiotensin II is not dependent on hepatic function. Therefore, the pharmacokinetics of Angiotensin II are not expected to be influenced by hepatic impairment. Age The effect of age was analyzed in the 163 patients receiving Angiotensin II in ATHOS-3. There were no significant differences in pharmacokinetics between age groups (< 65 years / ≥ 65 years). Male and Female Patients The effect of sex was analyzed in the 163 patients receiving Angiotensin II in ATHOS-3. There were no significant differences in pharmacokinetics between male and female patients."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions reported in greater than 10% in Angiotensin II treated patients were thromboembolic events. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma at (609)-250‐7990 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ATHOS-3 The safety of Angiotensin II was evaluated in ATHOS-3 [see Warnings and Precautions (5.1) ] . Patients in ATHOS-3 were receiving other vasopressors in addition to Angiotensin II or placebo, which were titrated to effect on mean arterial pressure (MAP). Table 2 summarizes adverse reactions with an incidence of at least 4% among patients treated with Angiotensin II and with a rate of at least 1.5% higher with Angiotensin II than with placebo. Table 2: Adverse Reactions Occurring in ≥ 4% of Patients Treated with Angiotensin II and ≥ 1.5% More Often than in Placebo-treated Patients in ATHOS-3 A dverse Event Angiotensin II N= 163 Placebo N= 158 Thromboembolic events a 21 (12.9%) 8 (5.1%) Deep vein thrombosis 7 (4.3%) 0 (0.0%) Thrombocytopenia 16 (9.8%) 11 (7.0%) Tachycardia 14 (8.6%) 9 (5.7%) Fungal infection 10 (6.1%) 2 (1.3%) Delirium 9 (5.5%) 1 (0.6%) Acidosis 9 (5.5%) 1 (0.6%) Hyperglycemia 7 (4.3%) 4 (2.5%) Peripheral ischemia 7 (4.3%) 4 (2.5%) a Including arterial and venous thrombotic events"],"contraindications":["4 CONTRAINDICATIONS None. None (4.1)"],"drug_interactions":["7 DRUG INTERACTIONS • Angiotensin converting enzyme (ACE) inhibitors ACE inhibitors may increase response to Angiotensin II. ( 7.1 ) • Angiotensin II Receptor Blockers (ARB) ARBs may reduce response to Angiotensin II. ( 7.2 ) 7.1. Angiotensin Converting Enzyme (ACE) Inhibitors Concomitant use of angiotensin converting enzyme (ACE) inhibitors may increase the response to Angiotensin II. 7.2. Angiotensin II Receptor Blockers (ARB) Concomitant use of angiotensin II blockers (ARBs) may decrease the response to Angiotensin II."],"mechanism_of_action":["12.1 Mechanism of Action Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein coupled-angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction."],"storage_and_handling":["16.2. Storage and Handling • Angiotensin II Injection vials should be stored in the refrigerator (36-46°F, 2-8°C). • Discard prepared diluted solution after 24 hours at room temperature or under refrigeration. Manufactured by: Gland Pharma Limited Hyderabad -502307, INDIA Revised: September, 2022"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein coupled-angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction. 12.2 Pharmacodynamics For the 114 (70%) patients in the Angiotensin II arm who reached the target MAP at Hour 3, the median time to reach the target MAP endpoint was approximately 5 minutes. Angiotensin II is titrated to effect for each individual patient. 12.3 Pharmacokinetics Following intravenous infusion of angiotensin II in adults with septic or other distributive shock, serum levels of angiotensin II are similar at Baseline and Hour 3 after intravenous infusion. After 3 hours of treatment, however, the serum level of angiotensin I (the angiotensin II precursor peptide) is reduced by approximately 40%. Distribution: No specific studies were conducted that examined the distribution of Angiotensin II. Metabolism and Excretion: No specific studies were conducted that examined the metabolism and excretion of Angiotensin II. The plasma half-life of IV administered angiotensin II is less than one minute. It is metabolized by aminopeptidase A and angiotensin converting enzyme 2 to angiotensin-(2-8) [angiotensin III] and angiotensin-(1-7), respectively in plasma, erythrocytes and many of the major organs (i.e., intestine, kidney, liver and lung). Angiotensin II type 1 receptor (AT1) mediated activity of angiotensin III is approximately 40% of angiotensin II; however, aldosterone synthesis activity is similar to angiotensin II. Angiotensin-(1-7) exerts the opposite effects of angiotensin II on AT1 receptors and causes vasodilation. Specific Populations No formal pharmacokinetic studies were conducted with Angiotensin II in the following specific populations. Renal Impairment The clearance of angiotensin II is not dependent on renal function. Therefore, the pharmacokinetics of Angiotensin II are not expected to be influenced by renal impairment. Hepatic Impairment The clearance of angiotensin II is not dependent on hepatic function. Therefore, the pharmacokinetics of Angiotensin II are not expected to be influenced by hepatic impairment. Age The effect of age was analyzed in the 163 patients receiving Angiotensin II in ATHOS-3. There were no significant differences in pharmacokinetics between age groups (< 65 years / ≥ 65 years). Male and Female Patients The effect of sex was analyzed in the 163 patients receiving Angiotensin II in ATHOS-3. There were no significant differences in pharmacokinetics between male and female patients."],"indications_and_usage":["1 INDICATIONS AND USAGE Angiotensin II Injection increases blood pressure in adults with septic or other distributive shock. Angiotensin II Injection is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive Angiotensin II. Use concurrent venous thromboembolism (VTE) prophylaxis. ( 5.1 , 6.1 ) 5.1 Risk for Thrombosis The safety of Angiotensin II was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received Angiotensin II compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No genetic toxicity studies have been conducted with Angiotensin II. No carcinogenicity or fertility studies with Angiotensin II have been conducted in animals. 13.2. Animal Toxicology and/or Pharmacology No animal toxicology studies were conducted with Angiotensin II. 13.3. Safety Pharmacology In a cardiovascular safety pharmacology study in normotensive dogs, Angiotensin II doses of 150, 450, and 1800 ng/kg (5, 15 and 60 ng/kg/min) were infused intravenously for 30 minutes each. At ≥ 450 ng/kg, Angiotensin II caused significantly elevated MAP and systemic vascular resistance, as expected. The 1800 ng/kg dose also caused increased heart rate, increased systemic vascular resistance, increased left ventricular systolic and end-diastolic pressures, and PR interval prolongation. Angiotensin II did not significantly alter respiratory rate or cause electrocardiographic changes in QRS duration or QTc."],"adverse_reactions_table":["
Adverse Event Angiotensin II N=163 Placebo N=158
Thromboembolic eventsa 21 (12.9%) 8 (5.1%)
Deep vein thrombosis 7 (4.3%) 0 (0.0%)
Thrombocytopenia 16 (9.8%) 11 (7.0%)
Tachycardia 14 (8.6%) 9 (5.7%)
Fungal infection 10 (6.1%) 2 (1.3%)
Delirium 9 (5.5%) 1 (0.6%)
Acidosis 9 (5.5%) 1 (0.6%)
Hyperglycemia 7 (4.3%) 4 (2.5%)
Peripheral ischemia 7 (4.3%) 4 (2.5%)
"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Dilute Angiotensin II Injection in 0.9% sodium chloride prior to use. See Full Prescribing Information for instructions on preparation and administration of injection. Diluted solution may be stored at room temperature or under refrigeration and should be discarded after 24 hours. Angiotensin II Injection must be administered as an intravenous infusion. ( 2.1 ) • Start Angiotensin II Injection intravenously at 20 nanograms (ng)/kg/min. Titrate as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed. During the first 3 hours, the maximum dose should not exceed 80 ng/kg/min. Maintenance dose should not exceed 40 ng/kg/min. ( 2.2 ) 2.1. Preparation Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Angiotensin II Injection must be administered as an intravenous infusion. Angiotensin II Injection must be diluted in 0.9% sodium chloride prior to use. Dilute the contents of one vial of Angiotensin II Injection in 0.9% saline to achieve a final concentration of 5,000 ng/mL or 10,000 ng/mL. Discard vial and any unused portion of the drug product after use. Table 1: Preparation of Diluted Solution F l u i d Restricted? V i al Strength Withdraw Amount (m L ) I n f usion Bag Size (mL) Final Concentration (ng/mL) No 2.5 mg/mL 1 500 5,000 Yes 2.5 mg/mL 1 250 10,000 Diluted solution may be stored at room temperature or under refrigeration. Discard prepared solution after 24 hours at room temperature or under refrigeration. 2.2. Administration The recommended starting dosage of Angiotensin II Injection is 20 nanograms (ng)/kg/min via continuous intravenous infusion. Administration through a central venous line is recommended. Monitor blood pressure response and titrate Angiotensin II Injection every 5 minutes by increments of up to 15 ng/kg/min as needed to achieve or maintain target blood pressure. Do not exceed 80 ng/kg/min during the first 3 hours of treatment. Maintenance doses should not exceed 40 ng/kg/min. Doses as low as 1.25 ng/kg/min may be used. Once the underlying shock has sufficiently improved, down-titrate every 5 to 15 minutes by increments of up to 15 ng/kg/min based on blood pressure."],"spl_product_data_elements":["ANGIOTENSIN II ANGIOTENSIN II ANGIOTENSIN II ANGIOTENSIN II MANNITOL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 2.5 mg/mL angiotensin II in a vial. Angiotensin II Injection is a clear, aqueous solution. Injection: 2.5 mg/mL in a vial."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The published data on angiotensin II use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have not been conducted with Angiotensin II. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or other distributive shock is likely to increase the risk of maternal and fetal morbidity and mortality. 8.2. Lactation Risk Summary It is not known whether Angiotensin II is present in human milk. No data are available on the effects of angiotensin II on the breastfed child or the effects on milk production. 8.4 Pediatric Use The safety and efficacy of Angiotensin II in pediatric patients have not been established. 8.5 Geriatric Use In ATHOS-3, 48% of the total patient population was aged 65 years and older. There was no significant difference in safety or efficacy between patients less than 65 and those 65 years or older when treated with Angiotensin II."],"dosage_and_administration_table":["
Fluid Restricted? Vial Strength Withdraw Amount (mL) Infusion Bag Size (mL) Final Concentration (ng/mL)
No 2.5 mg/mL 1 500 5,000
Yes 2.5 mg/mL 1 250 10,000
"],"animal_pharmacology_and_or_toxicology":["13.2. Animal Toxicology and/or Pharmacology No animal toxicology studies were conducted with Angiotensin II."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Carton label NDC 68083-553-01 1 x 1 mL single-dose vial Angiotensin II Injection 2.5 mg/mL Must dilute prior to intravenous infusion. Rx Only Single-dose vial Discard unused portion Container label 1 mL single-dose vial NDC 68083-553-01 Angiotensin II Injection 2.5 mg/mL Must dilute prior to intravenous infusion. Discard unused portion Rx Only angiotensin-II-carton-label angiotensin-II-container-label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No genetic toxicity studies have been conducted with Angiotensin II. No carcinogenicity or fertility studies with Angiotensin II have been conducted in animals."]},"tags":[{"label":"Vasoconstrictor [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Intravenous","category":"route"},{"label":"Solution","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"septic shock","category":"indication"},{"label":"distributive shock","category":"indication"},{"label":"La Jolla Pharma","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"62 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"27 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"22 reports"},{"date":"","signal":"PERIPHERAL ISCHAEMIA","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"DISTRIBUTIVE SHOCK","source":"FDA FAERS","actionTaken":"14 reports"},{"date":"","signal":"OVERDOSE","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"BRADYCARDIA","source":"FDA FAERS","actionTaken":"11 reports"}],"drugInteractions":[{"drug":"Angiotensin converting enzyme (ACE) inhibitors","severity":"moderate","mechanism":"May increase the response to Angiotensin II","management":"Monitor response and adjust dosage if necessary","clinicalEffect":"Increased response to Angiotensin II"},{"drug":"Angiotensin II Receptor Blockers (ARB)","severity":"moderate","mechanism":"May reduce the response to Angiotensin II","management":"Monitor response and adjust dosage if necessary","clinicalEffect":"Decreased response to Angiotensin II"}],"commonSideEffects":[{"effect":"Thromboembolic events","drugRate":"12.9%","severity":"serious","_validated":true},{"effect":"Thrombocytopenia","drugRate":"9.8%","severity":"serious","_validated":true},{"effect":"Tachycardia","drugRate":"8.6%","severity":"common","_validated":true},{"effect":"Delirium","drugRate":"5.5%","severity":"common","_validated":true},{"effect":"Acidosis","drugRate":"5.5%","severity":"common","_validated":true},{"effect":"Fungal infection","drugRate":"6.1%","severity":"common","_validated":true},{"effect":"Deep vein thrombosis","drugRate":"4.3%","severity":"mild","_validated":true},{"effect":"Hyperglycemia","drugRate":"4.3%","severity":"mild","_validated":true},{"effect":"Peripheral ischemia","drugRate":"4.3%","severity":"mild","_validated":true}],"contraindications":[],"specialPopulations":{"Pregnancy":"The published data on angiotensin II use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have not been conducted with Angiotensin II. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or other distributive shock is likely to increase the risk of maternal and fetal morbidity and mortality.","Geriatric use":"In ATHOS-3, 48% of the total patient population was aged 65 years and older. There was no significant difference in safety or efficacy between patients less than 65 and those 65 years or older when treated with Angiotensin II.","Paediatric use":"The safety and efficacy of Angiotensin II in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"La Jolla Pharma","patents":[{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2034","useCode":"U-2218","territory":"US","drugProduct":false,"patentNumber":"9220745","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 16, 2029","useCode":"U-2231","territory":"US","drugProduct":false,"patentNumber":"9867863","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2034","useCode":"U-2338","territory":"US","drugProduct":false,"patentNumber":"10028995","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Jul 18, 2031","useCode":"U-2221","territory":"US","drugProduct":false,"patentNumber":"9572856","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 16, 2029","useCode":"U-2581","territory":"US","drugProduct":false,"patentNumber":"10335451","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 16, 2029","useCode":"U-2740","territory":"US","drugProduct":false,"patentNumber":"10548943","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2034","useCode":"U-2679","territory":"US","drugProduct":false,"patentNumber":"10493124","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 16, 2029","useCode":"U-2681","territory":"US","drugProduct":false,"patentNumber":"10500247","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2034","useCode":"U-3514","territory":"US","drugProduct":false,"patentNumber":"11559559","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Jan 6, 2037","useCode":"U-3262","territory":"US","drugProduct":false,"patentNumber":"11219662","drugSubstance":false},{"applNo":"N209360","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2034","useCode":"U-3211","territory":"US","drugProduct":false,"patentNumber":"11096983","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ANGIOTENSIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:45:13.067844+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:45:13.067737+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Angiotensin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:45:20.219867+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:45:45.626755+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:45:18.418208+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:45:11.445361+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ANGIOTENSIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:45:18.957772+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:10.942346+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:10.942375+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:40.206140+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:10.942385+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:45:20.624677+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:32.122150+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2391146/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:45:19.821798+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA216966","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:10.942390+00:00"}},"allNames":"angiotensin ii","offLabel":[],"synonyms":["Angiotensin Ii","ANGIOTENSIN II"],"timeline":[{"date":"2025-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Gland to La Jolla Pharma"},{"date":"2025-06-03","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"},{"date":"20250603","type":"positive","source":"OpenFDA","milestone":"FDA approval (Gland)"}],"aiSummary":"Angiotensin II, marketed by La Jolla Pharma, is an approved treatment for septic or other distributive shock, leveraging its mechanism of action through receptor binding to constrict blood vessels. The drug's key strength lies in its unique mechanism, which addresses a critical unmet need in shock management. The primary risk is the key composition patent expiry in 2028, which could introduce generic competition and impact revenue.","approvals":[{"date":"20250603","orphan":false,"company":"GLAND","regulator":"FDA"}],"brandName":"Angiotensin Ii","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Vasoconstrictor [EPC]","explanation":"Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein coupled-angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.","oneSentence":"Angiotensin II works by binding to its receptor, triggering a cascade of signals that ultimately lead to the constriction of blood vessels.","technicalDetail":"Angiotensin II exerts its effects through the activation of the angiotensin type 1 receptor (AT1R), which triggers a Gq-mediated signaling cascade that ultimately leads to the contraction of smooth muscle cells and the constriction of blood vessels."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Angiotensin","title":"Angiotensin","extract":"Angiotensin is a peptide hormone that causes vasoconstriction and an increase in blood pressure. It is part of the renin–angiotensin system, which regulates blood pressure. Angiotensin also stimulates the release of aldosterone from the adrenal cortex to promote sodium retention by the kidneys."},"commercial":{"launchDate":"2025","_launchSource":"OpenFDA (20250603, GLAND)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"ANGIOTENSIN\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"ANGIOTENSIN\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=angiotensin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=angiotensin","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://en.wikipedia.org/wiki/Angiotensin","fields":["history","overview"],"source":"Wikipedia"},{"id":6,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:20:57.976585","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:45:45.627139+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"angiotensin","indications":{"approved":[{"id":"angiotensin-septic-or-other-distributive-s","name":"Septic or other distributive shock","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults with septic or other distributive shock","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults with septic or other distributive shock","diagnosticRequired":null,"brandNameForIndication":"Angiotensin Ii"}],"offLabel":[],"pipeline":[]},"currentOwner":"La Jolla Pharma","drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07295522","phase":"PHASE4","title":"Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2026-04-08","conditions":["Heart Failure","Acute Heart Failure","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)","Heart Failure With Mildly Reduced Ejection Fraction"],"enrollment":368,"completionDate":"2028-06-08"},{"nctId":"NCT07312292","phase":"PHASE2","title":"Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)","status":"RECRUITING","sponsor":"Niek Wijnen","startDate":"2026-01-01","conditions":["Liver Cancer (Locally Advanced or Metastatic)","Liver Cancer Adult"],"enrollment":15,"completionDate":"2027-11-01"},{"nctId":"NCT06183437","phase":"PHASE4","title":"The STOP-MED CTRCD Trial","status":"RECRUITING","sponsor":"Dinesh Thavendiranathan","startDate":"2024-03-04","conditions":["Heart Failure","Cardiotoxicity","Cardiac Toxicity","Antineoplastics Toxicity","Cancer"],"enrollment":335,"completionDate":"2031-12"},{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":["Diabetes Mellitus","High Blood Pressure","Cardiovascular Diseases","Cognitive Impairment"],"enrollment":9476,"completionDate":"2026-05-31"},{"nctId":"NCT06072508","phase":"NA","title":"Prognostic Interest of Vasorin in Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2023-07-03","conditions":["Sepsis","Acute Kidney Injury"],"enrollment":50,"completionDate":"2025-03-29"},{"nctId":"NCT05168787","phase":"","title":"Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2020-08-13","conditions":["Heart Failure"],"enrollment":6558,"completionDate":"2025-07-08"},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":["COVID19","Influenza Vaccination","ACE Inhibitors","ARB","Antihistamine Allergy","Amantadine"],"enrollment":3000,"completionDate":"2028-02-24"},{"nctId":"NCT04901169","phase":"PHASE2,PHASE3","title":"Angiotensin II in Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-06-28","conditions":["Liver Transplant; Complications","Vasoplegia"],"enrollment":50,"completionDate":"2027-03-18"},{"nctId":"NCT07169422","phase":"NA","title":"Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2026-03-01","conditions":["Diabetic Kidney Disease","Type 2 Diabetes","Chronic Kidney Disease"],"enrollment":120,"completionDate":"2028-07-01"},{"nctId":"NCT04789733","phase":"NA","title":"The GUARDIAN Pilot Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2021-04-27","conditions":["General Surgery"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT05457283","phase":"PHASE3","title":"A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-11-08","conditions":["Chronic Kidney Disease","Proteinuria","Children"],"enrollment":100,"completionDate":"2029-02-27"},{"nctId":"NCT06746753","phase":"PHASE4","title":"Dysfunctional Renin-Angiotensin System in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-03","conditions":["Septic Shock"],"enrollment":78,"completionDate":"2028-08"},{"nctId":"NCT04640610","phase":"","title":"Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-30","conditions":["Adenoidectomy","Tonsillectomy"],"enrollment":0,"completionDate":"2021-06-30"},{"nctId":"NCT07465666","phase":"","title":"A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-01","conditions":["Hypertension"],"enrollment":500,"completionDate":"2027-04-18"},{"nctId":"NCT06693726","phase":"PHASE4","title":"Early Angiotensin II in the Emergency Department","status":"RECRUITING","sponsor":"Brett A Faine","startDate":"2025-04-01","conditions":["Septic Shock"],"enrollment":20,"completionDate":"2026-11-30"},{"nctId":"NCT06588686","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.","status":"RECRUITING","sponsor":"Vicore Pharma AB","startDate":"2024-12-09","conditions":["Idiopathic Pulmonary Fibrosis (IPF)"],"enrollment":360,"completionDate":"2027-06"},{"nctId":"NCT06975111","phase":"PHASE2,PHASE3","title":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-03-01","conditions":["Menopause","Menopause Hot Flashes","Menopause Related Conditions","Cardiovascular"],"enrollment":200,"completionDate":"2030-10-01"},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":["Intracerebral Hemorrhage"],"enrollment":140,"completionDate":"2030-06-30"},{"nctId":"NCT04456816","phase":"PHASE2","title":"A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2020-08-31","conditions":["Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy","Severe Proteinuria Due to Idiopathic Membranous Nephropathy"],"enrollment":23,"completionDate":"2026-06-30"},{"nctId":"NCT07447206","phase":"PHASE2","title":"Vascular Intervention Strategies Trial for Alzheimer's","status":"NOT_YET_RECRUITING","sponsor":"University of Southern California","startDate":"2026-03","conditions":["Hypertension","Hypercholesterolemia","Dementia Risk Factors"],"enrollment":10,"completionDate":"2028-06"},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":["Diabetic Nephropathies","Kidney Diseases","Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2"],"enrollment":200,"completionDate":"2028-11-12"},{"nctId":"NCT07167368","phase":"NA","title":"Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients","status":"RECRUITING","sponsor":"Haiyan Pan","startDate":"2025-09-15","conditions":["Cardiorenal Syndrome"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT05855746","phase":"PHASE3","title":"Colchicine Versus Placebo in Acute Myocarditis Patients","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-07-16","conditions":["Acute Myocarditis"],"enrollment":300,"completionDate":"2028-07-16"},{"nctId":"NCT07292493","phase":"","title":"Immune System in Diabetic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Centre Ljubljana","startDate":"2025-12-01","conditions":["Diabetes","Diabetic Kidney Disease","Complement System"],"enrollment":90,"completionDate":"2028-12"},{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":["Coronary Artery Disease"],"enrollment":2476,"completionDate":"2026-09-14"},{"nctId":"NCT07044700","phase":"","title":"Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2028-01-31","conditions":["Heart Failure of Reduced Ejection Fraction (HFrEF)"],"enrollment":5000,"completionDate":"2028-12-31"},{"nctId":"NCT06749418","phase":"EARLY_PHASE1","title":"Vascular Effects of High-Salt After Preeclampsia","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2025-01-02","conditions":["Preeclampsia","Preeclampsia Postpartum"],"enrollment":40,"completionDate":"2027-11-15"},{"nctId":"NCT07099677","phase":"NA","title":"Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk","status":"RECRUITING","sponsor":"Abant Izzet Baysal University","startDate":"2025-08-01","conditions":["Hypertension","Fall Risk","Postural Balance","Fear of Falling"],"enrollment":186,"completionDate":"2026-06-30"},{"nctId":"NCT03593317","phase":"PHASE2","title":"Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-12-20","conditions":["Arrhythmogenic Right Ventricular Dysplasia"],"enrollment":120,"completionDate":"2029-12"},{"nctId":"NCT05196035","phase":"PHASE3","title":"A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-03-28","conditions":["Chronic Kidney Disease","Proteinuria"],"enrollment":219,"completionDate":"2027-08-31"},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":["Septic Shock","Vasodilatory Shock"],"enrollment":40,"completionDate":"2025-03-12"},{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":["Hypertension"],"enrollment":35,"completionDate":"2026-12-31"},{"nctId":"NCT06764277","phase":"","title":"Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis","status":"COMPLETED","sponsor":"Bernardo Rodríguez Iturbe","startDate":"2023-08-14","conditions":["Arterial Hypertension","Hemodialysis"],"enrollment":32,"completionDate":"2025-06-06"},{"nctId":"NCT05183646","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB","status":"RECRUITING","sponsor":"Dimerix Bioscience Pty Ltd","startDate":"2022-05-30","conditions":["FSGS"],"enrollment":286,"completionDate":"2029-12"},{"nctId":"NCT03856632","phase":"PHASE4","title":"Liraglutide Effect in Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2019-03-18","conditions":["Atrial Fibrillation"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT07374484","phase":"","title":"Longitudinal Dynamics of AT1R Antibodies in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2024-12-10","conditions":["Kidney Transplantation","Graft Survival","Angiotensin II Type 1 Receptor Antibody"],"enrollment":241,"completionDate":"2025-12-09"},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":["COVID-19","Cardiovascular Diseases"],"enrollment":372,"completionDate":"2024-12-30"},{"nctId":"NCT04849806","phase":"","title":"Sympathetic Nerve Activity Predictors in Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"RWTH Aachen University","startDate":"2022-05-10","conditions":["COPD","Sympathetic Nervous System Diseases","Catecholamine; Overproduction"],"enrollment":135,"completionDate":"2028-12"},{"nctId":"NCT04828161","phase":"PHASE2,PHASE3","title":"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-10","conditions":["COVID-19"],"enrollment":407,"completionDate":"2022-01-27"},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":["Heart Failure With Reduced Ejection Fraction","Coronary Artery Disease"],"enrollment":654,"completionDate":"2028-01-30"},{"nctId":"NCT07355023","phase":"NA","title":"AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","status":"RECRUITING","sponsor":"Tri-Service General Hospital","startDate":"2026-01-01","conditions":["Left Ventricular (LV) Systolic Dysfunction"],"enrollment":5000,"completionDate":"2026-01-15"},{"nctId":"NCT06933706","phase":"PHASE2","title":"Losartan to Improve Outcomes After Multi-ligament Knee Injury","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-01","conditions":["Multi-ligament Knee Injury"],"enrollment":90,"completionDate":"2029-09-30"},{"nctId":"NCT03806283","phase":"","title":"Mechanisms of Pregnancy Vascular Adaptations","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2018-11-20","conditions":["Pre-Eclampsia","Vascular Diseases"],"enrollment":166,"completionDate":"2027-04"},{"nctId":"NCT07347925","phase":"","title":"Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2026-01-10","conditions":["Heart Failure"],"enrollment":140,"completionDate":"2026-05-01"},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":["Severe Aortic Valve Stenosis"],"enrollment":25,"completionDate":"2027-05-30"},{"nctId":"NCT05530655","phase":"EARLY_PHASE1","title":"A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2024-02-20","conditions":["Prostate Cancer","Radiation Toxicity","Urinary Complication"],"enrollment":30,"completionDate":"2028-01-01"},{"nctId":"NCT07315191","phase":"PHASE4","title":"Finerenone Therapy for Pediatric HSPN With Mild Proteinuria","status":"RECRUITING","sponsor":"Capital Institute of Pediatrics, China","startDate":"2025-06-13","conditions":["Henoch Schönlein Purpura Nephritis"],"enrollment":116,"completionDate":"2028-04-30"},{"nctId":"NCT05834803","phase":"NA","title":"Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-06-26","conditions":["Renovascular Hypertension","Renovascular Hypertension With Renal Failure","Heart Failure","Renal Artery Stenosis Atherosclerotic","Percutaneous Transluminal Angioplasty"],"enrollment":80,"completionDate":"2027-06-01"},{"nctId":"NCT07315139","phase":"NA","title":"Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-01","conditions":["Pentoxifylline","Inflammatory Markers","Non-Diabetic","Chronic Kidney Disease"],"enrollment":42,"completionDate":"2023-08-31"},{"nctId":"NCT06023576","phase":"PHASE2","title":"A Study of Blood Pressure Control During Cancer Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-08-18","conditions":["Breast Cancer","Cardiotoxicity"],"enrollment":130,"completionDate":"2028-05-30"},{"nctId":"NCT06185660","phase":"","title":"A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-09","conditions":["Hyperkalaemia"],"enrollment":125,"completionDate":"2025-01-03"},{"nctId":"NCT06952608","phase":"PHASE4","title":"Effect of Ciprofol on Intraoperative Hypotension in Elderly Patients Receiving Renin-angiotensin System Inhibitors","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-10","conditions":["Intraoperative Hypotension","Ciprofol","Renin-angiotensin System Inhibitors"],"enrollment":140,"completionDate":"2026-04-10"},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":["Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","Chronic Kidney Disease Stage 1","Chronic Kidney Disease Stage 2","Obesity","Diabetes Mellitus, Type 2"],"enrollment":250,"completionDate":"2028-12-31"},{"nctId":"NCT04510792","phase":"","title":"IMpact of hyPeRkalaemia on thErapy With Renin angiotenSin aldoSterone System Inhibitors","status":"WITHDRAWN","sponsor":"Portsmouth Hospitals NHS Trust","startDate":"2021-07-12","conditions":["Hyperkalemia"],"enrollment":0,"completionDate":"2021-07-12"},{"nctId":"NCT06487585","phase":"PHASE4","title":"ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)","status":"RECRUITING","sponsor":"University of Maryland St. Joseph Medical Center","startDate":"2025-05-06","conditions":["Vasodilatory Hypotension During or After Cardiac Surgery"],"enrollment":100,"completionDate":"2026-02"},{"nctId":"NCT06256991","phase":"PHASE4","title":"Potassium Correction for RAAS Optimization in Chronic Kidney Disease","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-04-01","conditions":["Chronic Kidney Diseases","Hyperkalemia","Hypertension"],"enrollment":44,"completionDate":"2027-12"},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":["AMI","STEMI","NSTEMI","Left Ventricular Dysfunction"],"enrollment":450,"completionDate":"2026-10-12"},{"nctId":"NCT02770066","phase":"","title":"A Prospective Danish National Registry of PTRA in Patients With Renovascular Hypertension","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2015-01-01","conditions":["Renal Artery Obstruction","Hypertension, Renovascular","Cardiovascular Diseases","Kidney Diseases"],"enrollment":160,"completionDate":"2035-01"},{"nctId":"NCT01037530","phase":"PHASE4","title":"Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2010-12","conditions":["Intermittent Claudicants"],"enrollment":33,"completionDate":"2012-12"},{"nctId":"NCT04752293","phase":"","title":"Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":["Hypertension","Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria"],"enrollment":125,"completionDate":"2026-12"},{"nctId":"NCT07259512","phase":"PHASE4","title":"Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure","status":"RECRUITING","sponsor":"Evi Liliek Wulandari","startDate":"2025-06-30","conditions":["Chronic Kidney Disease","Heart Failure With Reduced Ejection Fraction (HFrEF)"],"enrollment":80,"completionDate":"2026-01-31"},{"nctId":"NCT01426529","phase":"PHASE1","title":"Caveolin-1 and Vascular Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-10-01","conditions":["Hypertension","Insulin Resistance"],"enrollment":120,"completionDate":"2026-10-15"},{"nctId":"NCT07262723","phase":"PHASE2,PHASE3","title":"Levosimendan in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Chittagong Medical College","startDate":"2025-12-01","conditions":["Acute Decompensated Heart Failure (ADHF)"],"enrollment":332,"completionDate":"2026-12-30"},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT05106036","phase":"NA","title":"Preventing Cognitive Decline by Reducing BP Target Trial","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-07-11","conditions":["Cognitive Decline","Blood Pressure","Hypertension"],"enrollment":4000,"completionDate":"2026-08-31"},{"nctId":"NCT07261098","phase":"PHASE2","title":"The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-01-01","conditions":["Advanced Lung Cancer"],"enrollment":200,"completionDate":"2028-12-31"},{"nctId":"NCT05498181","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-10-11","conditions":["Hemodialysis"],"enrollment":100,"completionDate":"2026-07-30"},{"nctId":"NCT07241338","phase":"PHASE4","title":"Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Jing Liu","startDate":"2025-11","conditions":["Hypertension"],"enrollment":104,"completionDate":"2027-06"},{"nctId":"NCT03188887","phase":"PHASE3","title":"Treatment of IgA Nephropathy According to Renal Lesions","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":["IgA Nephropathy"],"enrollment":62,"completionDate":"2024-01-12"},{"nctId":"NCT05989503","phase":"PHASE4","title":"Initiation of ARNi and SGLT2i in Patients With HFrEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2023-08-04","conditions":["Heart Failure With Reduced Ejection Fraction"],"enrollment":62,"completionDate":"2025-07-31"},{"nctId":"NCT04023227","phase":"PHASE4","title":"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-10","conditions":["Chagas Disease","Heart Failure"],"enrollment":918,"completionDate":"2025-03-31"},{"nctId":"NCT06862115","phase":"PHASE3","title":"The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery","status":"RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2025-03-01","conditions":["Myocardium; Injury","Perioperative/Postoperative Complications","Angiotensin-Converting-Enzyme Inhibitor"],"enrollment":156,"completionDate":"2026-01-01"},{"nctId":"NCT05049616","phase":"PHASE4","title":"Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-10-18","conditions":["Hypertension in Pregnancy","Postpartum Preeclampsia"],"enrollment":70,"completionDate":"2023-09-01"},{"nctId":"NCT02133872","phase":"PHASE2","title":"Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-10","conditions":["Hypertension"],"enrollment":34,"completionDate":"2018-11-01"},{"nctId":"NCT07212686","phase":"PHASE4","title":"Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension","status":"ENROLLING_BY_INVITATION","sponsor":"Todd Sweberg","startDate":"2025-09-09","conditions":["Vasodilatory Shock"],"enrollment":30,"completionDate":"2030-06"},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":["Chronic Heart Failure","Chronic Heart Failure With Reduced Ejection Fraction"],"enrollment":4936,"completionDate":"2025-09-19"},{"nctId":"NCT04983823","phase":"NA","title":"Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)","status":"RECRUITING","sponsor":"Baker Heart and Diabetes Institute","startDate":"2021-11-18","conditions":["Heart Failure"],"enrollment":820,"completionDate":"2025-12-30"},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":["Chronic Obstructive Pulmonary Disease","Pulmonary Artery Hypertension","Heart Failure","Hypertension"],"enrollment":420,"completionDate":"2026-08"},{"nctId":"NCT06700213","phase":"","title":"Guideline Directed Medical Therapy in Patients With Heart Failure","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2023-09-22","conditions":["Heart Failure"],"enrollment":300,"completionDate":"2025-09-22"},{"nctId":"NCT07181135","phase":"PHASE3","title":"FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-12-01","conditions":["Chronic Kidney Disease"],"enrollment":180,"completionDate":"2027-12-31"},{"nctId":"NCT07184918","phase":"NA","title":"Effect of Continuing vs. Discontinuing ACE Inhibitors on Renal Function After Coronary Angiography","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-02-01","conditions":["Contrast-Induced Nephropathy","Coronary Angiography","Acute Kidney Injury"],"enrollment":44,"completionDate":"2025-06-01"},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":["Peripartum Cardiomyopathy, Postpartum"],"enrollment":250,"completionDate":"2028-12-31"},{"nctId":"NCT05990296","phase":"NA","title":"Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care","status":"COMPLETED","sponsor":"Geisinger Clinic","startDate":"2023-08-01","conditions":["Heart Failure","Heart Failure With Reduced Ejection Fraction"],"enrollment":4306,"completionDate":"2025-05-17"},{"nctId":"NCT06482853","phase":"EARLY_PHASE1","title":"Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2025-01-23","conditions":["Obesity","Hypertension"],"enrollment":52,"completionDate":"2029-03"},{"nctId":"NCT03777215","phase":"EARLY_PHASE1","title":"Angiotensin-(1-7) and Energy Expenditure in Human Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amy Arnold","startDate":"2019-09-26","conditions":["Obesity"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT05301192","phase":"EARLY_PHASE1","title":"Angiotensin-(1-7) Cardiovascular Effects in Aging","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-12-09","conditions":["Aging"],"enrollment":26,"completionDate":"2026-12"},{"nctId":"NCT00962949","phase":"PHASE1","title":"The Renin-Aldosterone Axis in Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2009-04","conditions":["Postural Orthostatic Tachycardia Syndrome (POTS)"],"enrollment":28,"completionDate":"2012-12"},{"nctId":"NCT04520048","phase":"NA","title":"Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-08-11","conditions":["Hypertension Disorders in Pregnancy","Gestational Hypertension","Pre-Eclampsia"],"enrollment":110,"completionDate":"2026-12"},{"nctId":"NCT04592744","phase":"PHASE4","title":"Angiotensin 2 for AKI After OLT","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Los Angeles","startDate":"2022-04-08","conditions":["Cirrhosis, Liver","End Stage Liver DIsease","Acute Kidney Injury","Liver Transplant; Complications"],"enrollment":30,"completionDate":"2026-03"},{"nctId":"NCT05272878","phase":"PHASE3","title":"Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-22","conditions":["Acute Kidney Injury"],"enrollment":508,"completionDate":"2026-06-27"},{"nctId":"NCT02472028","phase":"PHASE4","title":"Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":["Cerebrovascular Disorders"],"enrollment":820,"completionDate":"2028-09-11"},{"nctId":"NCT04884802","phase":"NA","title":"The GUARDIAN Trial","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-07-25","conditions":["Blood Pressure"],"enrollment":6254,"completionDate":"2027-04-25"},{"nctId":"NCT06704633","phase":"PHASE4","title":"Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania","status":"NOT_YET_RECRUITING","sponsor":"Martin Rohacek","startDate":"2026-01-05","conditions":["Heart Failure"],"enrollment":238,"completionDate":"2028-04-30"},{"nctId":"NCT06917664","phase":"PHASE4","title":"Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-06-05","conditions":["Coronary Artery Disease","Ischemic Mitral Regurgitation","Angiotensin Receptor/Neprilysin Inhibitor"],"enrollment":220,"completionDate":"2027-06"},{"nctId":"NCT05937841","phase":"EARLY_PHASE1","title":"Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia","status":"RECRUITING","sponsor":"Anna Stanhewicz, PhD","startDate":"2023-06-28","conditions":["Preeclampsia Postpartum"],"enrollment":30,"completionDate":"2026-06-01"},{"nctId":"NCT03733145","phase":"PHASE4","title":"Angiotensin II in General Anesthesia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-10-03","conditions":["Hypertension"],"enrollment":32,"completionDate":"2023-03-21"},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":["PreDiabetes","Impaired Glucose Tolerance","Obesity","Blood Pressure"],"enrollment":90,"completionDate":"2026-06"},{"nctId":"NCT07088471","phase":"","title":"Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Connolly Hospital Blanchardstown","startDate":"2024-11-01","conditions":["Heart Failure and Reduced Ejection Fraction"],"enrollment":334,"completionDate":"2025-08-01"},{"nctId":"NCT05331144","phase":"PHASE2","title":"Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)","status":"RECRUITING","sponsor":"Rong Zhang","startDate":"2022-10-25","conditions":["Cognitively Normal Older Adults","Hypertension","Subjective Cognitive Decline","Family History of Dementia"],"enrollment":180,"completionDate":"2027-12-31"},{"nctId":"NCT06150560","phase":"PHASE3","title":"A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-01","conditions":["Coarctation of Aorta","High Blood Pressure"],"enrollment":120,"completionDate":"2028-06-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Solution","formulations":[{"form":"SOLUTION","route":"INTRAVENOUS","productName":""}]},"_patentsChecked":true,"crossReferences":{"UNII":"M089EFU921","RXCUI":"1999007","SPL_ID":"db7a3372-cd0e-412e-a8e2-90b5fdcf3e3e","chemblId":"CHEMBL2391146"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2025-","companyName":"Gland","relationship":"Original Developer"},{"period":"present","companyName":"La Jolla Pharma","relationship":"Current Owner"}],"publicationCount":134351,"therapeuticAreas":["Hematology"],"applicationNumber":"ANDA216966","biosimilarFilings":[],"originalDeveloper":"Gland","recentPublications":[{"date":"2026 Mar 30","pmid":"41912901","title":"[Extrapulmonary sarcoidosis with multiorgan involvement: a complex case with renal, neurological, and gastrointestinal manifestations].","journal":"Innere Medizin (Heidelberg, Germany)"},{"date":"2026 Mar 30","pmid":"41912806","title":"The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.","journal":"Nature medicine"},{"date":"2026 Mar 1","pmid":"41910487","title":"Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury: Insights from the Chronic Renal Insufficiency Cohort Study.","journal":"Kidney360"},{"date":"2026 Jan-Dec","pmid":"41909498","title":"Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis.","journal":"Kidney diseases (Basel, Switzerland)"},{"date":"2026 Feb","pmid":"41909425","title":"A Minimalist Approach With Maximum Outcomes: Intralesional Steroid Therapy in Orofacial Sarcoidosis.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Gland"],"status":"active","companyName":"La Jolla Pharma","companyId":"la-jolla-pharma","modality":"Recombinant protein","firstApprovalDate":"2025","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-12-21T00:00:00.000Z","mah":"LA JOLLA PHARMA","brand_name_local":null,"application_number":"NDA209360"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-06-03T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA216966"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"GLAND","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"GLAND","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"GLAND","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"GLAND","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"GLAND","brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"GLAND","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:45:45.627139+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}